AYER, Mass.--(EON: Enhanced Online News)--Cambrooke Therapeutics Inc., an innovation leader in therapeutic nutrition for inborn errors of metabolism and ketogenic diet therapy, launches the long awaited baking mix, KetoVie Café Kwik Mix 4.5:1, to its popular line of a ketogenic foods.
KetoVie Café Kwik Mix 4.5:1 is easy to use and has the versatility to make a variety of your favorite baked goods, such as muffins, cookies and quick breads. As Cambrooke continues to extend its line of ketogenic diet-friendly products for those with intractable epilepsy, the company works tirelessly to ensure the products are convenient, tasty and packed with nutrition.
The smooth texture of the KetoVie Café Kwik Mix 4.5:1 was designed to be a quick-mix baking blend that can be used to create delicious recipes. Pancakes and waffles are just a few child-friendly foods that will be a hit among both kids and adults of any age. KetoVie Café Kwik Mix 4.5:1 is available in a 1.5-pound re-sealable bag and can be stored up to six months in the refrigerator, and has 1.1g of net carb and a 4.5:1 ketogenic ratio.
“My daughter Luella was all grins and smiles when she heard about the new mix and that she would be able to have ketogenic waffles on a regular basis. She still remembers the first time she tasted the KetoVie Café Waffle during the product development stages. The KetoVie Café Kwik Mix 4.5:1 is wonderful, and I look forward to the many everyday smiles to come when we use the Kwik Mix to make delicious recipes. The prep time to bake and try new things has made all the faces in the household cheer and smile,” says Luella’s mother, Renee K.
KetoVie Café Kwik Mix 4.5:1 is available for direct purchase via www.ketovie.com or calling 866-456-9776.
About Cambrooke Therapeutics – Founded in 2000, Cambrooke Therapeutics, Inc. is a private equity-backed, Massachusetts-based therapeutic nutrition company and global provider of medical nutrition products for patients with serious unmet medical needs. The company works with physicians and researchers from around the world to develop, test and commercialize products that are today focused on inborn errors of metabolism and intractable epilepsy. More information is available at www.cambrooketherapeutics.com.